JP2016534984A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534984A5
JP2016534984A5 JP2016519325A JP2016519325A JP2016534984A5 JP 2016534984 A5 JP2016534984 A5 JP 2016534984A5 JP 2016519325 A JP2016519325 A JP 2016519325A JP 2016519325 A JP2016519325 A JP 2016519325A JP 2016534984 A5 JP2016534984 A5 JP 2016534984A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
heteroaryl
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534984A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/064998 external-priority patent/WO2015049651A1/en
Publication of JP2016534984A publication Critical patent/JP2016534984A/ja
Publication of JP2016534984A5 publication Critical patent/JP2016534984A5/ja
Pending legal-status Critical Current

Links

JP2016519325A 2013-10-01 2014-10-01 アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物 Pending JP2016534984A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361885146P 2013-10-01 2013-10-01
US61/885,146 2013-10-01
US201462025994P 2014-07-17 2014-07-17
US62/025,994 2014-07-17
PCT/IB2014/064998 WO2015049651A1 (en) 2013-10-01 2014-10-01 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent

Publications (2)

Publication Number Publication Date
JP2016534984A JP2016534984A (ja) 2016-11-10
JP2016534984A5 true JP2016534984A5 (OSRAM) 2017-11-16

Family

ID=51743521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519325A Pending JP2016534984A (ja) 2013-10-01 2014-10-01 アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物

Country Status (12)

Country Link
US (2) US9809558B2 (OSRAM)
EP (1) EP3052483B1 (OSRAM)
JP (1) JP2016534984A (OSRAM)
KR (1) KR20160060660A (OSRAM)
CN (1) CN105593222B (OSRAM)
AU (1) AU2014330781B2 (OSRAM)
BR (1) BR112016007371A2 (OSRAM)
CA (1) CA2925862A1 (OSRAM)
ES (1) ES2721098T3 (OSRAM)
RU (1) RU2016117052A (OSRAM)
SG (1) SG11201601870VA (OSRAM)
WO (1) WO2015049651A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10697983B2 (en) 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies
US20170066839A1 (en) * 2015-09-08 2017-03-09 Merck Patent Gmbh Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies
US10697982B2 (en) 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies
JPWO2018181738A1 (ja) * 2017-03-30 2020-02-13 日立化成株式会社 分離材
JP7688395B2 (ja) * 2018-11-26 2025-06-04 ノース カロライナ ステイト ユニヴァーシティ 宿主細胞タンパク質の捕捉のためのペプチドリガンド
TW202024134A (zh) 2018-12-21 2020-07-01 大陸商江蘇恆瑞醫藥股份有限公司 雙特異性蛋白
LT4069691T (lt) 2019-12-06 2024-12-10 Vertex Pharmaceuticals Incorporated Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
BR112023026747A2 (pt) 2021-06-18 2024-03-12 Aligos Therapeutics Inc Métodos e composições para direcionamento de pd-l1
US12428427B2 (en) 2021-12-16 2025-09-30 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH187973A4 (de) * 1973-02-09 1977-03-31 Hoechst Ag Verfahren zum optischen Aufhellen von Textilmaterialien
US4722896A (en) 1981-01-26 1988-02-02 The Beth Israel Hospital Association Method for affinity purification of hybridoma antibodies
US5849874A (en) 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
JP2825755B2 (ja) * 1993-04-07 1998-11-18 大塚製薬株式会社 ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体
CA2182731A1 (en) * 1994-02-03 1995-08-10 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2481334A1 (en) 2002-04-01 2003-10-16 Anthony C. Stevens Tissue-specific endothelial membrane proteins
DE60326735D1 (de) * 2002-08-02 2009-04-30 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
WO2007056155A1 (en) 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
BR112012002280B1 (pt) 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
JP5744886B2 (ja) * 2009-10-19 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロペンタンカルボキサミド誘導体、このような化合物を含む薬物及びそれらの使用
EP2601208B1 (en) 2010-08-03 2015-02-11 Graffinity Pharmaceuticals GmbH LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY
WO2012020080A2 (en) 2010-08-12 2012-02-16 Graffinity Pharmaceuticals Gmbh LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof

Similar Documents

Publication Publication Date Title
JP2016534984A5 (OSRAM)
RU2016117052A (ru) Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства
JP2006524222A5 (OSRAM)
JP2013517283A5 (OSRAM)
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
JP2014511869A5 (OSRAM)
JP2008516986A5 (OSRAM)
JP2020512373A5 (OSRAM)
JP2016053042A5 (OSRAM)
JP2010506825A5 (OSRAM)
JP2010540462A5 (OSRAM)
JP2007519695A5 (OSRAM)
JP2014521653A5 (OSRAM)
PE20141375A1 (es) Activadores de glucoquinasa
PE20081530A1 (es) Nuevos compuestos 617
JP2016503009A5 (OSRAM)
JP2016505614A5 (OSRAM)
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2016540811A5 (OSRAM)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2017518344A5 (OSRAM)
RU2010142936A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРАЗИНА КАК ИНГИБИТОРЫ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ
HRP20191554T1 (hr) Derivat azol benzena
JP2016508135A5 (OSRAM)
HRP20140588T1 (hr) Spojevi kondenziranog prstena i njihova uporaba